Shinobi Therapeutics
Latest round
- Series A
Last raised
- Aug 2024
Total raised
- $78M
Investors
- 9
About Shinobi Therapeutics
a. Shinobi operates a biotechnology company that focuses on developing a new class of immune-evasive iPS-T cell therapies for cancer treatment. In December 2023, Shinobi Therapeutics Inc.ß iPS-T cells. These cells, with plug-and-play antigen specificity, offer cancer treatment by providing increased persistence, reduced lymphodepletion, redosability, and off-the-shelf availability.ß T cell), and NJA-005 (pancreatic beta cell) used for iPSC-derived cell therapies.
Who invested in Shinobi Therapeutics
9 investors across 2 rounds
See all investors in Shinobi Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Shinobi Therapeutics
Who invested in Shinobi Therapeutics?
Shinobi Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shinobi Therapeutics raised?
Shinobi Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Shinobi Therapeutics last raise money?
Shinobi Therapeutics's most recent round on record is a Series A, in Aug 2024.
What does Shinobi Therapeutics do?
Shinobi Therapeutics is a biotechnology company.
Where is Shinobi Therapeutics headquartered?
Shinobi Therapeutics is headquartered in South San Francisco, US.
Which VCs invest in companies like Shinobi Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Shinobi Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Shinobi Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.